Copy to clipboard 
Smith+Nephew kicked off 2026 with significant strategic activity. The company closed its transaction with Integrity Orthopedics and entered into three strategic relationships to strengthen its offerings in sports medicine and fracture fixation.
An Acquisition in Sports Medicine
In January the company closed the purchase of Integrity Orthopaedics, expanding its sports medicine shoulder repair business with a suite of technologies available for rotator cuff repair (RCR).
Integrity developed Tendon Seam, a biomechanical alternative to the present standard of care in RCR. Now available in the U.S. and complementary to the REGENETEN Bioinductive Implant, the system offers a differentiated RCR portfolio.
Tendon Seam allows for a novel repair stitch configuration with multiple points of fixation. Its microanchors, continuous suture, individually locked stitches, and integrated implantation instrument are designed to deliver stronger repairs, accelerated patient recovery, lower re-tear rates, and a simplified surgical technique.
Similar to post-acquisition efforts with REGENETEN, Smith+Nephew plans to accelerate adoption of Tendon Seam by leveraging its commercial channels in the U.S. while building a base of evidence to support global adoption.
Three Partnerships to Close the Quarter
By the end of 1Q, Smith+Nephew entered distribution collabs to bolster sports medicine and also fracture fixation.
KARL STORZ North America teamed up with the company to offer complementary visualization solutions.
The companies will align Smith+Nephew’s sports medicine portfolio with KARL STORZ’s visualization, video management, and operating room integration technologies in support of hospital ORs and ASCs—particularly, multi-specialty environments.
KARL STORZ’s expertise includes 3D imaging and near-infrared fluorescence. Smith+Nephew’s foundation offers applications that span joint repair implants, biologics, cartilage repair, RF technology, mechanical resection, and fluid management.
A distribution agreement with SI-BONE centers on their iFuse TORQ portfolio. This collaboration expands the Smith+Nephew’s offerings for percutaneous pelvic fracture fixation and supports their position in high-frequency, high-impact trauma procedures.
The iFuse TORQ line includes iFuse TORQ TNT and iFuse TORQ implants, offering indications for pelvic fracture fixation and fusion of the sacroiliac joint. Specifically, iFuse TORQ TNT is designed to address anatomical and bone density needs of the sacrum and ilium.
Smith+Nephew will have access to the broader iFuse TORQ portfolio alongside SI-BONE’s current sales channel, expanding the ability to serve surgeons and patients.
Finally, the company signed an exclusive U.S. distribution agreement with RMR Ortho to add the A’TOMIC Nitinol Fixation System to its trauma, foot & ankle and hand & wrist portfolio.
A’TOMIC Nitinol Fixation leverages proprietary manufacturing and the properties of nitinol to provide compressive fixation implants that feature a wide bridge with barbed, round legs that match drill holes. The system is engineered to achieve stability of fusion, fracture and osteotomy sites through high strength and active compression.
In quarterly coverage, analyst Caitlin Roberts of Canaccord Genuity noted, “We see SNN as working to leverage its strengths (sports medicine, smaller format robotics) with its recent/upcoming launches and acquisitions (CORI for shoulder, Tendon Seam), which, over the long term, we believe could help it compete more effectively.”
ORTHOWORLD’s analyst Mike Evers observed that at the close of 2025, “The company delivered its strongest quarterly growth in over two years. This performance was driven by a third consecutive quarter of above-market growth in U.S. hips, improving knee performance and continued strong growth in the company’s Trauma and Extremities business.”
We look forward to learning how these strategic movements from the start of 2026 contribute throughout the year.
Smith+Nephew kicked off 2026 with significant strategic activity. The company closed its transaction with Integrity Orthopedics and entered into three strategic relationships to strengthen its offerings in sports medicine and fracture fixation.
An Acquisition in Sports Medicine
In January the company closed the purchase of Integrity...
Smith+Nephew kicked off 2026 with significant strategic activity. The company closed its transaction with Integrity Orthopedics and entered into three strategic relationships to strengthen its offerings in sports medicine and fracture fixation.
An Acquisition in Sports Medicine
In January the company closed the purchase of Integrity Orthopaedics, expanding its sports medicine shoulder repair business with a suite of technologies available for rotator cuff repair (RCR).
Integrity developed Tendon Seam, a biomechanical alternative to the present standard of care in RCR. Now available in the U.S. and complementary to the REGENETEN Bioinductive Implant, the system offers a differentiated RCR portfolio.
Tendon Seam allows for a novel repair stitch configuration with multiple points of fixation. Its microanchors, continuous suture, individually locked stitches, and integrated implantation instrument are designed to deliver stronger repairs, accelerated patient recovery, lower re-tear rates, and a simplified surgical technique.
Similar to post-acquisition efforts with REGENETEN, Smith+Nephew plans to accelerate adoption of Tendon Seam by leveraging its commercial channels in the U.S. while building a base of evidence to support global adoption.
Three Partnerships to Close the Quarter
By the end of 1Q, Smith+Nephew entered distribution collabs to bolster sports medicine and also fracture fixation.
KARL STORZ North America teamed up with the company to offer complementary visualization solutions.
The companies will align Smith+Nephew’s sports medicine portfolio with KARL STORZ’s visualization, video management, and operating room integration technologies in support of hospital ORs and ASCs—particularly, multi-specialty environments.
KARL STORZ’s expertise includes 3D imaging and near-infrared fluorescence. Smith+Nephew’s foundation offers applications that span joint repair implants, biologics, cartilage repair, RF technology, mechanical resection, and fluid management.
A distribution agreement with SI-BONE centers on their iFuse TORQ portfolio. This collaboration expands the Smith+Nephew’s offerings for percutaneous pelvic fracture fixation and supports their position in high-frequency, high-impact trauma procedures.
The iFuse TORQ line includes iFuse TORQ TNT and iFuse TORQ implants, offering indications for pelvic fracture fixation and fusion of the sacroiliac joint. Specifically, iFuse TORQ TNT is designed to address anatomical and bone density needs of the sacrum and ilium.
Smith+Nephew will have access to the broader iFuse TORQ portfolio alongside SI-BONE’s current sales channel, expanding the ability to serve surgeons and patients.
Finally, the company signed an exclusive U.S. distribution agreement with RMR Ortho to add the A’TOMIC Nitinol Fixation System to its trauma, foot & ankle and hand & wrist portfolio.
A’TOMIC Nitinol Fixation leverages proprietary manufacturing and the properties of nitinol to provide compressive fixation implants that feature a wide bridge with barbed, round legs that match drill holes. The system is engineered to achieve stability of fusion, fracture and osteotomy sites through high strength and active compression.
In quarterly coverage, analyst Caitlin Roberts of Canaccord Genuity noted, “We see SNN as working to leverage its strengths (sports medicine, smaller format robotics) with its recent/upcoming launches and acquisitions (CORI for shoulder, Tendon Seam), which, over the long term, we believe could help it compete more effectively.”
ORTHOWORLD’s analyst Mike Evers observed that at the close of 2025, “The company delivered its strongest quarterly growth in over two years. This performance was driven by a third consecutive quarter of above-market growth in U.S. hips, improving knee performance and continued strong growth in the company’s Trauma and Extremities business.”
We look forward to learning how these strategic movements from the start of 2026 contribute throughout the year.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
